Ingenuity canonical pathways | −log(p value) | Ratio | Molecules |
---|---|---|---|
D-myo-inositol-5-phosphate metabolism | 2.85 | 0.0641 | DOT1L, INPP5B, MDP1, NUDT5, PLCG1, PPIP5K1, PPP2R5A, PTPN6, PTPRM, SET |
Superpathway of inositol phosphate compounds | 2.12 | 0.0505 | DOT1L, INPP5B, MDP1, NUDT5, PLCG1, PPIP5K1, PPP2R5A, PTPN6, PTPRM, SET |
Endocannabinoid cancer inhibition pathway | 2.04 | 0.0559 | ATF3, CREB1, GNB1L, LEF1, MAP2K4, PRKACA, SPTLC1, TCF4 |
Heme biosynthesis II | 1.87 | 0.222 | HMBS, UROD |
Folate transformations I | 1.87 | 0.222 | MTHFD2, MTHFR |
Salvage pathways of pyrimidine ribonucleotides | 1.84 | 0.0619 | CSNK1D, GRK4, MAP2K4, MAPK6, PRKCH, UCKL1 |
Protein kinase a signaling | 1.76 | 0.0377 | ADD1, ADD3, APEX1, CHP1, CREB1, FLNA, GNB1L, LEF1, PLCG1, PRKACA, PRKCH, PTPN4, PTPN6, PTPRM, TCF4 |
Amyloid processing | 1.73 | 0.08 | CAPN2, CSNK1D, PRKACA, PSEN2 |
Androgen signaling | 1.66 | 0.0515 | GNA12, GNB1L, KAT7, NCOA1, POLR2J2/POLR2J3, PRKACA, PRKCH |
Virus entry via endocytic pathways | 1.65 | 0.0561 | AP2A1, FLNA, ITGAL, ITGB1, PLCG1, PRKCH |